Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRIS 
Curis Inc (CRIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CRIS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.33
1 Year Target Price $16.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.1% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.75M USD | Price to earnings Ratio - | 1Y Target Price 16.33 |
Price to earnings Ratio - | 1Y Target Price 16.33 | ||
Volume (30-day avg) 5 | Beta 3.8 | 52 Weeks Range 1.02 - 6.34 | Updated Date 09/15/2025 |
52 Weeks Range 1.02 - 6.34 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -300.15% |
Management Effectiveness
Return on Assets (TTM) -59.59% | Return on Equity (TTM) -2951.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14918912 | Price to Sales(TTM) 1.99 |
Enterprise Value 14918912 | Price to Sales(TTM) 1.99 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 12498900 | Shares Floating 9745106 |
Shares Outstanding 12498900 | Shares Floating 9745106 | ||
Percent Insiders 7.23 | Percent Institutions 34.32 |
Upturn AI SWOT
Curis Inc
Company Overview
History and Background
Curis, Inc. is a biotechnology company focused on developing and commercializing innovative drug candidates for the treatment of human cancers. Founded in 2000, Curis has focused on identifying and validating novel drug targets and developing drug candidates that address unmet medical needs in oncology. The company has undergone strategic shifts, including focusing on specific drug candidates and indications.
Core Business Areas
- Drug Development: Curis focuses on the discovery, development, and commercialization of therapeutics for the treatment of cancer. Their pipeline includes investigational drugs targeting various cancer pathways.
Leadership and Structure
Curis's leadership team consists of a Chief Executive Officer, Chief Medical Officer, and other key executives. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Emavusertib: Emavusertib is a first-in-class oral IRAK4 inhibitor being evaluated in lymphoma and other hematologic malignancies. The company has not yet generated substantial revenue and is focused on ongoing clinical trials and potential future regulatory approvals. Competitors developing similar therapies include companies focusing on IRAK4 inhibition and related pathways.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Advances in genomics, proteomics, and other areas of science are driving the development of new therapies for cancer.
Positioning
Curis is a small biotechnology company focused on developing targeted therapies for cancer. Its competitive advantage lies in its specific drug candidates, such as emavusertib and its intellectual property. Its ability to secure funding and successfully navigate clinical trials will be critical to its success.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is substantial and continually growing. Curis's positioning within this market is dependent on the success of its drug candidates and their potential to address unmet needs in specific cancer indications. The market size is estimated to be over $200 Billion annually. Curis's potential TAM depends on the success of Emavusertib and other pipeline drugs.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Focus on targeted cancer therapies
- Experienced management team
- Intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- No currently marketed products
- High risk of failure in drug development
Opportunities
- Potential for regulatory approval of drug candidates
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in personalized medicine
Threats
- Competition from larger pharmaceutical companies
- Unfavorable clinical trial results
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- GILD
Competitive Landscape
Curis faces intense competition from larger pharmaceutical and biotechnology companies. Its advantages include its novel drug candidates and its focus on targeted therapies. Its disadvantages include its limited financial resources and its dependence on clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Curis's historical growth has been driven by its drug development programs and its ability to raise capital. It has experienced periods of rapid growth followed by periods of contraction.
Future Projections: Future projections are dependent on the success of its drug candidates and its ability to secure funding. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing clinical trials of emavusertib, seeking strategic partnerships, and optimizing its research and development pipeline.
Summary
Curis Inc. is a high-risk, high-reward biotechnology company focused on developing novel cancer therapies. While the company has promising drug candidates, it faces significant challenges including limited financial resources and the inherent risks of drug development. Success hinges on positive clinical trial results, strategic partnerships, and securing funding, but their lack of market share and acquisition history makes them a weak player in the industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Curis Inc. investor relations
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market information are subject to change. Clinical trial outcomes are inherently uncertain. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curis Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-08-01 | President, CEO, Secretary, Treasurer & Director Mr. James E. Dentzer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.curis.com |
Full time employees 34 | Website https://www.curis.com | ||
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.